Dec. 23 at 2:43 PM
Truist reiterated
$VRDN Buy-
$41, and said: 'Veli's Priority Review & June 30 PDUFA Set, Confirming Clean, Catalyst-Rich 2026 Set-Up'
$AMGN $IMVT NVS ARGX
Truist added: This morning's BLA acceptance and priority review for Veli' comes in as expected, though reinforcing of the solid and still-underappreciated execution and opportunity available for VRDN and shares give the clean and attractive set-up across the portfolio; a June 30 PDUFA with robust launch preparations underway open the door to a mid-2026 launch - our base case - and VRDN's foray into TED.
On the path for pivotal SC data in early 2026, a mid-year IV PDUFA, and potential launch later this year, we like the multi-pronged but direct-course appreciation potential on VRDN shares and reiterate our Buy rating and
$41 price target.
